Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

CV Sciences (CVSI) Accounts Payables (2016 - 2025)

Historic Accounts Payables for CV Sciences (CVSI) over the last 14 years, with Q3 2025 value amounting to $1.2 million.

  • CV Sciences' Accounts Payables fell 3563.1% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 3563.1%. This contributed to the annual value of $1.9 million for FY2024, which is 1663.06% down from last year.
  • Per CV Sciences' latest filing, its Accounts Payables stood at $1.2 million for Q3 2025, which was down 3563.1% from $1.4 million recorded in Q2 2025.
  • CV Sciences' 5-year Accounts Payables high stood at $2.7 million for Q1 2022, and its period low was $646000.0 during Q2 2021.
  • Over the past 5 years, CV Sciences' median Accounts Payables value was $2.2 million (recorded in 2022), while the average stood at $2.0 million.
  • Per our database at Business Quant, CV Sciences' Accounts Payables skyrocketed by 28281.73% in 2022 and then crashed by 3918.7% in 2025.
  • Over the past 5 years, CV Sciences' Accounts Payables (Quarter) stood at $2.6 million in 2021, then decreased by 12.96% to $2.3 million in 2022, then increased by 1.09% to $2.3 million in 2023, then dropped by 16.63% to $1.9 million in 2024, then plummeted by 36.94% to $1.2 million in 2025.
  • Its Accounts Payables stands at $1.2 million for Q3 2025, versus $1.4 million for Q2 2025 and $1.5 million for Q1 2025.